S&P 500 Financials Sector SEC Filings — January 11, 2026

12-01-2026

Jaguar Health, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009221, Size: 506 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), Item 3.02 (Unregistered Sales of Equity Securities), and Item 9.01 (Financial Statements and Exhibits). No specific details on the core event, transaction size, counterparties, terms, or financial impacts are disclosed in the provided filing summary. This is a multi-item mandatory disclosure indicating a significant financing-related transaction.

12-01-2026

USANA Health Sciences Inc filed an 8-K on January 12, 2026 (AccNo: 0000896264-26-000005, size 177 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure with no specific revenue, earnings, or other metrics detailed in the provided information. Sector not specified.

12-01-2026

Kura Oncology, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009649), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a multi-item filing focused on financial results.

12-01-2026

Tempus AI, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009650, size 174 KB) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction values, or quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001187, Size: 225 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financial impacts provided in the summary. Sector not specified.

12-01-2026

IDEAYA Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009641, Size: 4 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, financial metrics, transaction values, or exhibit contents are explicitly stated in the provided filing summary. Sector is not specified.

12-01-2026

Guardant Health, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001576280-26-000004, Size: 202 KB), disclosing Results of Operations and Financial Condition under Item 2.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This is a financial results announcement typical for quarterly earnings releases. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

MBX Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009642, Size: 263 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific numerical data, transaction details, or financial metrics are disclosed in the provided information.

12-01-2026

Thermo Fisher Scientific Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000871, Size: 310 KB), disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements. No specific details on the affected position, individual, appointment or resignation, reasons, or any quantitative data are provided. Sector is not specified.

12-01-2026

Veracyte, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001384101-26-000002, Size: 186 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure event. No specific revenue, earnings, transaction values, or other quantitative metrics are disclosed in the provided filing summary.

12-01-2026

Terra Property Trust, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002583, Size: 198 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

TEVA PHARMACEUTICAL INDUSTRIES LTD filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000174, Size: 244 KB), reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a multi-item filing related to financial results.

12-01-2026

Cracker Barrel Old Country Store, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002590, Size: 2 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, financial data, transactions, or exhibits are disclosed in the provided filing summary. This is a multi-item filing with voluntary disclosure elements under Regulation FD.

12-01-2026

Pelican Acquisition Corp announced a Merger/Acquisition event via an 8-K filing on January 12, 2026 (AccNo: 0001829126-26-000189, Size: 271 KB), including Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on deal structure, parties involved, valuation, or financial terms are disclosed in the provided filing metadata. Sector is not specified.

12-01-2026

Katapult Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000950103-26-000342, Size: 253 KB) disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements. No specific details on the key position affected, appointment or resignation, reasons, named individuals, or other impacts are provided. Sector is not specified.

12-01-2026

Rise Gold Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001062993-26-000154, Size: 240 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Telomir Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001170, Size: 206 KB), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. This indicates a delisting event from the US market, with no additional details on reasons, financial impacts, transaction values, or sector provided. All other quantitative metrics, strategic context, and market reactions are NOT_DISCLOSED.

12-01-2026

Sensus Healthcare, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001753926-26-000088, Size: 215 KB), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 lists financial statements and exhibits. No specific details on the affected officer, position, reason for change, or quantitative data provided in the filing summary.

12-01-2026

Edwards Lifesciences Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001099800-26-000002, Size: 203 KB) reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with no specific details on the disclosure content or attached exhibits provided. Sector is not specified.

12-01-2026

Inspire Veterinary Partners, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003112, size: 591 KB), reporting multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 2.03 (Creation of a Direct Financial Obligation), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), and 9.01 (Financial Statements and Exhibits). Specific details including transaction values, parties, share counts, dollar amounts, strategic context, or financial impacts are NOT_DISCLOSED in the provided summary. Sector is not specified.

12-01-2026

Twin Vee PowerCats, Co. filed a Form 8-K on January 12, 2026 (AccNo: 0001731122-26-000038, Size: 190 KB) disclosing an event under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Sector is not specified. No specific details on positions, individuals, reasons, or quantitative data are provided in the filing summary.

12-01-2026

QXO, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002656, Size: 282 KB), disclosing Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on transaction values, parties, share counts, or financial impacts provided in the summary. Sector is not specified.

12-01-2026

EACO CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002560, Size: 269 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, transaction values, percentages, or other quantitative financial metrics are mentioned in the provided filing summary. Sector is not specified.

12-01-2026

Intuit Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000896878-26-000004, Size: 1 MB), disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. This is a multi-item mandatory filing with no specific transaction details, dollar values, or terms provided in the summary. Core event involves a material agreement and new financial obligation.

12-01-2026

Hamilton Beach Brands Holding Co filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009679, Size: 2 MB) reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction values, or financial metrics are disclosed in the provided filing summary.

12-01-2026

Niocorp Developments Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001539497-26-000036, Size: 471 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US SEC. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Regeneron Pharmaceuticals, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002691, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. This is a multi-item filing focused on financial results disclosure.

12-01-2026

J.Jill, Inc. filed a Form 8-K on January 12, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). Accession Number: 0001193125-26-009691; File size: 259 KB. No specific details on the disclosed information, events, financials, or exhibits are provided in the filing summary.

12-01-2026

Venture Global, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0002007855-26-000002, Size: 202 KB), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or detailed outcomes are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Duolingo, Inc. disclosed an Officer Change event via Form 8-K filed on 2026-01-12 (AccNo: 0001628280-26-001730, Size: 10 MB), covering Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer involved, nature of change (appointment/resignation), reasons, or financial metrics are provided in the summary. Sector is not specified.

12-01-2026

WEX Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000891, Size: 1 MB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Regulation FD Disclosure under Item 7.01. No specific details on the affected officer, position, reason for change, or any quantitative data are provided in the summary. Sector is not specified.

12-01-2026

Enovis CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001206, Size: 7 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing with no specific event details, transaction values, or financial metrics disclosed in the provided summary. Sector is not specified.

12-01-2026

Lindsay Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009690, Size: 171 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders), and Item 9.01 (Financial Statements and Exhibits). No specific details on positions affected, reasons for change, voting outcomes, or exhibits are provided. Sector is not specified.

12-01-2026

UNITEDHEALTH GROUP INC filed a Form 8-K on January 12, 2026 (AccNo: 0000731766-26-000020, Size: 190 KB) reporting under Item 7.01 Regulation FD Disclosure. No specific details on the disclosure content, events, transactions, or financial metrics are provided in the filing summary. Sector is not specified.

12-01-2026

Axsome Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009744, Size: 269 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure, but no specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary. All detailed financial impacts, guidance, or events remain NOT_DISCLOSED.

12-01-2026

News Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001564708-26-000007, Size: 401 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing information. Sector not specified.

12-01-2026

Citi Trends Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002693, Size: 217 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing from the US SEC with no sector specified. No core event details, financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary.

12-01-2026

US Foods Holding Corp. filed an 8-K on January 12, 2026 (AccNo: 0001665918-26-000002, Size: 308 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure with no specific numerical financial metrics, transaction values, or other quantitative details provided in the filing summary. Event type is Financial Results from the US market, sector not specified.

12-01-2026

CareDx, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001217234-26-000007, Size: 192 KB), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. This is a financial results disclosure from the US market, sector not specified. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.

12-01-2026

TriSalus Life Sciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001743, Size: 209 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

Trinseo PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002698, Size: 256 KB), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. Item 9.01 includes financial statements and exhibits. No specific details on positions, names, reasons, or quantitative data provided in the filing summary.

12-01-2026

Uber Technologies, Inc. filed a Form 8-K on January 12, 2026, under Item 8.01 Other Events. Accession Number: 0001543151-26-000005, File Size: 1 MB. No details on the specific event, transaction, or financial impacts are disclosed in the provided filing information.

12-01-2026

Annexon, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009740, Size: 176 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Vince Holding Corp. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009731, Size: 10 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other specific information are disclosed in the filing summary. Sector is not specified.

12-01-2026

Moderna, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001682852-26-000007, Size: 179 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure. No specific financial metrics, transaction values, or other numerical data are disclosed in the provided filing summary.

12-01-2026

BioXcel Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002697, Size: 196 KB) under Item 8.01 Other Events. No specific details on the event, transaction, financial impacts, or other quantitative data are provided in the filing summary. Sector not specified.

12-01-2026

Karyopharm Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009738, Size: 314 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This appears to be a financial results announcement from the US market. No specific numerical data, transaction details, or further content from the filing is provided.

12-01-2026

Passage BIO, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002696, Size: 20 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction details, or quantitative data are provided in the filing summary.

12-01-2026

Portillo's Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001871509-26-000003, Size: 4 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the Regulation FD disclosure or the nature of the exhibits are disclosed in the filing summary. This is a voluntary disclosure under Regulation FD with no core event, transaction details, or financial metrics mentioned.

12-01-2026

IONIS PHARMACEUTICALS INC filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000893, Size: 209 KB) reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This appears to be a standard financial results disclosure.

12-01-2026

Neurogene Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001404644-26-000003, Size: 4 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the disclosures, events, transactions, or financial data are provided in the filing summary.

12-01-2026

Palvella Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009724, Size: 26 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing from the US SEC with sector not specified. No specific details on events, transactions, financials, or exhibits are disclosed in the provided filing summary.

12-01-2026

NovoCure Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001645113-26-000003, Size: 225 KB) reporting Item 2.02: Results of Operations and Financial Condition and Item 9.01: Financial Statements and Exhibits. This is a financial results disclosure from the US market, with sector not specified. No specific numerical financial metrics, transaction details, or further content from the filing is provided.

12-01-2026

Oxford Industries Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000199, size 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing with no specific event details, transaction values, or financial metrics disclosed in the provided summary. Sector not specified.

12-01-2026

XOMA Royalty Corp filed a Form 8-K on January 12, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with Accession No. 0001193125-26-009726 and file size 2 MB. No core event details, transaction values, financial metrics, or other specifics are disclosed in the provided filing information.

12-01-2026

OrthoPediatrics Corp filed an 8-K on January 12, 2026 (AccNo: 0001425450-26-000003, Size: 880 KB) reporting financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, transaction values, percentages, or other quantitative financial metrics are disclosed in the provided filing summary. This is a multi-item filing focused on earnings disclosure with no details on outcomes or impacts.

12-01-2026

Aclaris Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002694, Size: 12 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure with no core event, transaction details, financial metrics, or quantitative data explicitly stated in the provided filing summary. All specific numbers, impacts, and entities beyond the filer are NOT_DISCLOSED.

12-01-2026

Neumora Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009727, Size: 5 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or attached exhibits are provided. Sector is not specified.

12-01-2026

Beam Therapeutics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009722, Size: 12 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results in the US equity market. No specific numerical data, transaction details, or financial metrics are disclosed in the provided filing summary.

12-01-2026

Henry Schein Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009725, Size: 596 KB), disclosing an officer change event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), with Item 9.01 (Financial Statements and Exhibits). No specific details on positions affected, individuals involved, reasons for changes, or quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

Utz Brands, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001735), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US SEC. No specific financial metrics, transaction values, or detailed outcomes are provided in the filing summary.

12-01-2026

NewtekOne, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001749, Size: 927 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided summary. All quantitative data, named entities, and material impacts are NOT_DISCLOSED.

12-01-2026

BICYCLE THERAPEUTICS PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002706, Size: 276 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Global Payments Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002705, Size: 735 KB), disclosing under Item 1.01 entry into a material definitive agreement, Item 2.01 completion of an acquisition or disposition of assets, Item 3.02 unregistered sales of equity securities, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. This indicates a merger/acquisition event for Global Payments Inc. in the US market, but no specific parties, deal structure, valuation, or financial metrics are disclosed.

12-01-2026

Agios Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific core event, transaction details, or numerical data disclosed in the provided filing summary. All quantitative metrics, named entities beyond the filer, and material impacts are NOT_DISCLOSED.

12-01-2026

Axogen, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000805928-26-000004, Size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative data are mentioned.

12-01-2026

Neogenomics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001628280-26-001746, Size: 275 KB), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election/appointment of directors/officers, or compensatory arrangements (Item 5.02), and financial statements/exhibits (Item 9.01). Event type is Officer Change from US SEC source. No specific details on the officer position, appointment/resignation, reasons, or financial metrics are provided.

12-01-2026

Dexcom Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001093557-26-000003, Size: 435 KB) under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, transaction values, or other quantitative metrics are disclosed in the provided filing summary. This is a routine earnings-related disclosure without detailed content available.

12-01-2026

Zumiez Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000201, Size: 219 KB), disclosing Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or specific financial statements/exhibits are provided. Sector not specified.

12-01-2026

Fidelity National Information Services, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009759, Size: 241 KB), reporting the completion of an acquisition or disposition of assets under Item 2.01, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No details on parties involved, deal structure, valuation, or strategic rationale are explicitly stated. Sector not specified.

12-01-2026

Wave Life Sciences Ltd. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009784, size 20 MB), disclosing under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Sotera Health Co filed a Form 8-K on January 12, 2026 (AccNo: 0001822479-26-000004, Size: 504 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction details, or quantitative data are provided in the filing summary.

12-01-2026

Pegasystems Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001013857-26-000009, Size: 139 KB) reporting under Item 2.05 costs associated with exit or disposal activities. No specific dollar values, transaction details, named entities, or quantitative metrics were disclosed in the provided filing summary. This disclosure signals potential restructuring or cost-related events requiring materiality assessment.

12-01-2026

Dyne Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009782, size: 16 MB), reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary.

12-01-2026

Corbus Pharmaceuticals Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009758, Size: 22 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on voluntary disclosure of potentially material information and attached exhibits. No specific event details, financial metrics, or transaction information are disclosed in the provided filing summary.

12-01-2026

European Wax Center, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009773, Size: 197 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, revenue, earnings, or other quantitative data are disclosed in the provided filing summary. This appears to be a standard earnings-related disclosure with no detailed content available.

12-01-2026

Stoke Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009781, Size: 177 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a financial results announcement classified as an Event Type: Financial Results from the US market. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Brookdale Senior Living Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001332349-26-000004, Size: 786 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This constitutes a multi-item voluntary financial results disclosure. No specific financial metrics, transaction values, or detailed results are provided in the filing summary.

12-01-2026

Harvard Bioscience Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000203, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or other specifics are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure focused on Regulation FD.

12-01-2026

Summit Therapeutics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001599298-26-000004, Size: 5 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US market. No specific financial metrics, transaction details, or quantitative data are provided in the filing summary.

12-01-2026

Lyra Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009772), disclosing costs associated with exit or disposal activities under Item 2.05, departure of directors or certain officers, election/appointment of directors/officers, and compensatory arrangements under Item 5.02, and other events under Item 8.01. Event classified as Officer Change. No specific numerical values, names, reasons, or details provided in the summary.

12-01-2026

Ultragenyx Pharmaceutical Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009791, size 227 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

EDAP TMS SA filed a Form 8-K on January 12, 2026 (Accession No. 0001171843-26-000204, 9 MB), reporting results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a financial results disclosure event. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

TScan Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009771, size: 4 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Alnylam Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001755, size 235 KB) under Item 2.02 reporting results of operations and financial condition. This is a financial results disclosure for a US biotech company. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Avalo Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001534120-26-000003, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

InnovAge Holding Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001834376-26-000003, Size: 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure, financial statements, exhibits, transactions, or quantitative metrics are provided in the filing summary. This is a multi-item filing likely voluntary in nature.

12-01-2026

Krystal Biotech, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001711279-26-000008, Size: 171 KB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary financial results announcement. No specific financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary.

12-01-2026

Emergent BioSolutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001367644-26-000003, Size: 210 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure related to Regulation FD.

12-01-2026

SunOpta Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001062993-26-000156, size 262 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

ProKidney Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009807, Size: 16 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, financial metrics, transaction values, or other specifics are disclosed in the filing summary. Sector is not specified.

12-01-2026

Nuvation Bio Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009826, Size: 5 MB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, financial results, transaction values, or other quantitative data provided in the summary. All key transaction and financial metrics are NOT_DISCLOSED.

12-01-2026

BillionToOne, Inc. filed an 8-K on January 12, 2026 (AccNo: 0002070849-26-000010, size 159 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Regulation FD Disclosure under Item 7.01. No specific financial metrics, transaction details, revenues, earnings, or guidance are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Vir Biotechnology, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001768, Size: 4 MB) under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific revenue, earnings, transaction values, or other quantitative metrics in the summary. No core event details, strategic impacts, or guidance changes are explicitly stated.

12-01-2026

Butterfly Network, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001804176-26-000002, Size: 201 KB) reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector not specified.

12-01-2026

BioLife Solutions Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001767, Size: 365 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure from the US market. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.

12-01-2026

SelectQuote, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001794783-26-000004, Size: 2 MB), reporting entry into a material definitive agreement (Item 1.01), termination of a material definitive agreement (Item 1.02), and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03). The filing also includes Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). No specific transaction details, dollar values, or other quantitative data are disclosed.

12-01-2026

MiMedx Group, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001376339-26-000003, size 3 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the Regulation FD disclosure content or exhibits are provided. This is a general filing from the US SEC with sector not specified.

12-01-2026

Akebia Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001517022-26-000003, Size: 4 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure of financial results. No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary.

12-01-2026

Noodles & Company filed an 8-K on January 12, 2026 (AccNo: 0001275158-26-000003, Size: 4 MB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Catalyst Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). Accession Number: 0001193125-26-009822; File Size: 2 MB. No specific details on the disclosed information, events, transactions, financial metrics, or exhibits are provided in the filing summary.

12-01-2026

CERUS CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009824, Size: 317 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This is a financial results disclosure from the US SEC. No specific revenue, earnings, transaction values, or other numerical financial metrics are mentioned.

12-01-2026

ABERCROMBIE & FITCH CO /DE/ filed a Form 8-K on January 12, 2026 (AccNo: 0001018840-26-000003), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing for material non-public information disclosure with attached exhibits. No core event details, transaction values, financial metrics, or other quantitative data are explicitly stated in the provided filing summary.

12-01-2026

ESTABLISHMENT LABS HOLDINGS INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001688757-26-000004, Size: 276 KB) under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a financial results disclosure with no specific revenue, earnings, or other quantitative metrics provided in the filing summary. Sector is not specified.

12-01-2026

Elanco Animal Health Inc filed a Form 8-K on January 12, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the disclosure content, core event, financial metrics, or transactions are provided in the filing summary. File size is 6 MB with Accession Number 0001104659-26-002723.

12-01-2026

Erasca, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009820, size: 17 MB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on events, transactions, financials, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Apyx Medical Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001048, Size: 208 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, revenue, earnings, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a financial results announcement with attached exhibits, sector not specified.

12-01-2026

Digi Power X Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003146, Size: 239 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the Regulation FD disclosure content or exhibits are provided in the filing summary. Sector not specified.

12-01-2026

ONE Group Hospitality, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002722, Size: 248 KB), reporting Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided information.

12-01-2026

Novavax Inc filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002725, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Bicara Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001766, Size: 301 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financials, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Planet Fitness, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001637207-26-000002, Size: 190 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No details on core events, transactions, financial impacts, or exhibits are disclosed in the provided summary. This appears to be a voluntary disclosure of potentially material information via Regulation FD.

12-01-2026

Cabaletta Bio, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009819, Size: 25 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 8.01 Other Events. No specific details on the core event, transaction, financial impacts, or other quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Protagonist Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002724, Size: 13 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the disclosures, events, transactions, or financial data are provided in the filing summary. Sector is not specified.

12-01-2026

Theravance Biopharma, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002726, Size: 14 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of potentially material non-public information with attached exhibits. Sector not specified; no specific event details, financial metrics, or transaction values disclosed in the provided summary.

12-01-2026

Oncology Institute, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001079973-26-000068, Size: 262 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This discloses financial results as a standard earnings-related filing. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Strategy Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009811, Size: 374 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 8.01 Other Events. No specific details on the core event, transaction, financial impacts, or quantitative data are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Digital Ally, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001493152-26-001231, Size: 671 KB), disclosing entry into a material definitive agreement (Item 1.01), completion of acquisition or disposition of assets (Item 2.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). No specific details on parties, deal structure, valuation, or financial terms are provided in the filing summary. Sector not specified.

12-01-2026

Galecto, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009812, size 16 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the Regulation FD disclosure content or exhibits are provided. Sector not specified.

12-01-2026

TransMedics Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009816, Size: 774 KB), reporting Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, events, transaction value, or financial impacts disclosed in the provided information. All quantitative metrics such as dollar values, share counts, or percentages are NOT_DISCLOSED.

12-01-2026

Kyverna Therapeutics, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009810, Size: 277 KB), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election/appointment of directors/officers, or compensatory arrangements (Item 5.02), and financial statements/exhibits (Item 9.01). Specific details on the officer change, including position affected, appointment/resignation status, reasons, or any quantitative data, are NOT_DISCLOSED. No sector specified.

12-01-2026

Fulcrum Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009845, size: 15 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary.

12-01-2026

Esperion Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001764, Size: 1 MB) reporting financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a standard disclosure for financial results with no specific numerical data, transaction details, or outcomes provided in the filing summary. Sector is not specified.

12-01-2026

Replimune Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002721, Size: 5 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other specifics are stated in the provided filing summary. All quantitative and material event data is NOT_DISCLOSED.

12-01-2026

Alkermes plc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009813, Size: 14 MB) reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely related to earnings release or financial updates, but no specific financial metrics, transaction details, or other quantitative data are disclosed in the provided information. Sector is not specified.

12-01-2026

Figure Technology Solutions, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001230, Size: 253 KB) reporting financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Adaptive Biotechnologies Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009840, size 8 MB), reporting Results of Operations and Financial Condition under Item 2.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

AmpliTech Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001229, Size: 288 KB), disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are provided in the filing summary. Sector is not specified.

12-01-2026

Twist Bioscience Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001581280-26-000012, Size: 200 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This discloses financial results as a routine earnings-related filing. No specific financial metrics, transaction values, or quantitative details are provided in the filing summary.

12-01-2026

Bionano Genomics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000904, Size: 202 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. Event type is Financial Results from the US market, with sector not specified.

12-01-2026

ADC Therapeutics SA filed a Form 8-K on January 12, 2026 (AccNo: 0000950103-26-000349, Size: 19 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with sector not specified. No core event details, financial metrics, transaction values, or other specifics are disclosed in the provided filing summary.

12-01-2026

CARLSMED, INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009828, Size: 178 KB) reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No quantitative financial metrics, transaction values, revenue, earnings, or other specific numbers are disclosed in the provided filing summary. This is a standard financial results disclosure with sector not specified.

12-01-2026

Bakkt Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009830, Size: 1 MB), reporting multiple material events under Items 1.01 (Entry into Material Definitive Agreement), 1.02 (Termination of Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure/Election/Appointment of Directors/Officers; Compensatory Arrangements), 5.03 (Amendments to Articles/Bylaws), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements/Exhibits). This is a multi-item mandatory filing with no specific transaction details, values, names, or financial impacts disclosed. Core events involve agreement changes, equity sales, governance shifts, and disclosures, signaling potential strategic or operational transitions.

12-01-2026

AtriCure, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009814, Size: 1 MB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing with no specific transaction details, dollar values, or financial metrics disclosed in the provided summary. Sector is not specified.

12-01-2026

Rigel Pharmaceuticals Inc filed an 8-K on January 12, 2026 (AccNo: 0001034842-26-000005, Size: 211 KB) reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US market, sector not specified. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Geron Corp filed a Form 8-K on January 12, 2026 (AccNo: 0000886744-26-000003, Size: 3 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on core events, transactions, financial metrics, or other specifics are provided in the filing summary. Sector is not specified.

12-01-2026

ClearPoint Neuro, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009867, Size: 187 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure from the US SEC with no specific revenue, earnings, transaction values, or other quantitative metrics mentioned. Sector is not specified.

12-01-2026

CVRx, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002728), reporting multiple items: Entry into a Material Definitive Agreement (Item 1.01), Results of Operations and Financial Condition (Item 2.02), Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement (Item 2.03), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). No specific details, transaction values, financial metrics, or named entities beyond the filer are disclosed in the provided summary. All quantitative data and core event descriptions are NOT_DISCLOSED.

12-01-2026

Mirum Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001759425-26-000004, Size: 9 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure of financial results. No specific numerical data, transaction details, or financial metrics are mentioned in the provided filing summary.

12-01-2026

Mereo BioPharma Group plc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009829, Size: 14 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure as Items 7.01 and 8.01 are typically voluntary. No specific core events, transactions, financial metrics, or quantitative data are explicitly stated in the provided filing summary.

12-01-2026

Senseonics Holdings, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002736, Size: 233 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data disclosed in the provided filing summary. Sector not specified.

12-01-2026

Day One Biopharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009834, Size: 8 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item financial results announcement. No specific financial metrics, transaction values, or quantitative data are mentioned in the provided filing summary.

12-01-2026

Turn Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003153, Size: 218 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing with no specific event details, transaction values, or financial metrics disclosed in the provided summary. Sector is not specified.

12-01-2026

Mind Medicine (MindMed) Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009854, Size: 14 MB), reporting Items 2.02 (Results of Operations and Financial Condition), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific financial metrics, transaction values, or detailed event descriptions provided in the summary. Analysis is limited to the disclosed item numbers.

12-01-2026

Hyperfine, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009859, Size: 7 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, with no specific revenue, earnings, transaction values, or other quantitative metrics provided in the summary. Sector is not specified.

12-01-2026

Progyny, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001551306-26-000009, Size: 165 KB) reporting Item 2.02: Results of Operations and Financial Condition as part of Financial Results. Sector is not specified. No specific financial metrics, transaction values, revenues, earnings, or other quantitative details are disclosed in the provided filing summary.

12-01-2026

Petco Health & Wellness Company, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009852), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the filing summary. Sector is not specified.

12-01-2026

Disc Medicine, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009871, Size: 15 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results with no specific numerical data, transaction details, or sector disclosed in the provided information. All quantitative financial metrics are NOT_DISCLOSED.

12-01-2026

Recursion Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001601830-26-000002, size: 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure or the nature of the financial statements/exhibits are provided. Sector is not specified.

12-01-2026

Kelly Services Inc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009849, Size: 231 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modifications to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, modifications, or disclosures provided in the available summary. All transaction values, financial metrics, and other quantitative data are NOT_DISCLOSED.

12-01-2026

ADMA Biologics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000906, size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or quantitative impacts are detailed in the provided filing summary.

12-01-2026

Perspective Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009846, Size: 285 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. No quantitative data, named entities beyond the filer, or material impacts are mentioned.

12-01-2026

Harmony Biosciences Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002731, size 7 MB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results announcement. No specific revenue, earnings, transaction values, or other quantitative financial metrics are mentioned in the provided filing summary.

12-01-2026

Amprius Technologies, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession number: 0001899287-26-000003; file size: 185 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.

12-01-2026

Allegiant Travel Co filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000907, Size: 8 MB), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, disclosures, or financials provided in the summary. Sector not specified.

12-01-2026

Myriad Genetics Inc filed a Form 8-K on January 12, 2026 (AccNo: 0000899923-26-000003), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or quantitative data are provided in the filing summary.

12-01-2026

Nurix Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001549595-26-000003, size 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure under Regulation FD.

12-01-2026

Autolus Therapeutics plc filed a Form 8-K on January 12, 2026 (AccNo: 0001730463-26-000012, Size: 7 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details on the events, transactions, financials, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Prime Medicine, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001628280-26-001773, Size: 6 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event, transaction details, numerical values, or specific content from the disclosures are provided in the filing summary. Sector is not specified.

12-01-2026

Moleculin Biotech, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001050, Size: 227 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific core event, transaction details, financial metrics, or numerical values disclosed in the provided summary. Sector is not specified.

12-01-2026

MACOM Technology Solutions Holdings, Inc. disclosed an Officer Change via Form 8-K filed on January 12, 2026 (AccNo: 0001493594-26-000002, Size: 207 KB). The filing covers Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer, position, reason for change, or quantitative data are provided in the summary.

12-01-2026

Acumen Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001774, Size: 8 MB), under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or quantitative data are explicitly stated in the provided filing summary. This appears to be a voluntary disclosure of other events with attached exhibits.

12-01-2026

OS Therapies Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003166, Size: 468 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction values, share counts, dollar amounts, named parties, or financial metrics disclosed in the provided information. All quantitative details such as transaction value, share count, and percentage changes are NOT_DISCLOSED.

12-01-2026

Outset Medical, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009865, Size: 7 MB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements), alongside Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position (e.g., CEO, CFO), nature of change (appointment or resignation), reasons, or financial metrics are disclosed. All quantitative data such as transaction values, share counts, or percentages is NOT_DISCLOSED.

12-01-2026

Sonoma Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001683168-26-000205, Size: 8 MB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Septerna, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009864, Size: 14 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the disclosure content, events, transactions, or financial metrics are provided in the filing summary. Sector is not specified.

12-01-2026

Clene Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001049, Size: 195 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Sadot Group Inc. filed an 8-K on January 12, 2026 (AccNo: 0001731122-26-000046, Size: 191 KB) reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No additional details on the core event, reasons, financial impacts, or quantitative metrics are provided in the filing summary. Sector is not specified.

12-01-2026

Microbot Medical Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001234, Size: 246 KB) under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financial statements, or exhibits are disclosed in the provided filing summary.

12-01-2026

Aardvark Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009862, Size: 11 MB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, or financial statements are provided in the filing summary. Sector not specified.

12-01-2026

Heartflow, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001464521-26-000005, Size: 10 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US market with sector not specified. No core event details, financial data, or transaction specifics are disclosed in the provided filing summary.

12-01-2026

Tarsus Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001819790-26-000002, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing focused on disclosing material non-public information and attaching exhibits. No specific event details, financial metrics, or transaction values are disclosed in the provided filing summary.

12-01-2026

Amphenol Corp (/DE/) filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002737, Size: 252 KB) disclosing the completion of an acquisition or disposition of assets under Item 2.01. The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No details on deal structure, parties, valuation, or strategic rationale are explicitly stated.

12-01-2026

Inogen Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009878, Size: 186 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results announcement from the US market. No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary.

12-01-2026

VisionWave Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001731122-26-000045, Size: 398 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. Sector not specified. No details on the agreement, transaction value, parties, or exhibits provided in the summary.

12-01-2026

CRISPR Therapeutics AG filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009880, Size: 167 KB) reporting under Item 8.01: Other Events. No details on the specific event, transaction, financial impacts, or quantitative metrics are disclosed in the provided filing summary. All numerical values, named entities beyond the filer, and material event specifics are NOT_DISCLOSED.

12-01-2026

BITMINE IMMERSION TECHNOLOGIES, INC. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing has Accession Number 0001493152-26-001237 and a file size of 254 KB. No specific details on the content of the disclosure, financials, or exhibits are provided in the summary.

12-01-2026

Quantum Computing Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003174, Size: 220 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financials provided in the summary. Sector not specified.

12-01-2026

Ondas Holdings Inc. filed Form 8-K on 2026-01-12 (AccNo: 0001213900-26-003169, Size: 1 MB) reporting Items 1.01 (Entry into a Material Definitive Agreement), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with Item 1.01 being mandatory disclosure of a material event. No specific details, transaction values, or financial metrics are disclosed in the provided filing summary.

12-01-2026

ELUTIA INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002742, Size: 173 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This is a financial results disclosure from the US market. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Foghorn Therapeutics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009885), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative data are mentioned.

12-01-2026

Osprey Bitcoin Trust filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001240, Size: 208 KB), reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 financial statements and exhibits. No details on the agreement, transaction value, parties involved, or financial impacts are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Soleno Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009886, Size: 167 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This constitutes a financial results disclosure, classified as Event Type: Financial Results from US SEC source. No specific revenue, earnings, transaction values, or other quantitative financial metrics are mentioned in the provided filing summary.

12-01-2026

Danaher Corp /DE/ filed an 8-K on January 12, 2026 (AccNo: 0000313616-26-000002, size: 2 MB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This is a financial results announcement from the US market.

12-01-2026

Avalon GloboCare Corp. filed an 8-K on January 12, 2026, reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). Accession Number: 0001213900-26-003178, file size 228 KB. No specific details on events, transactions, or financial metrics are disclosed in the provided filing summary.

12-01-2026

Pacific Biosciences of California, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001299130-26-000005, Size: 184 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, quantitative data, or other substantive content from the filing is provided in the summary. Sector is not specified.

12-01-2026

Exagen Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001274737-26-000003, size 175 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or numerical values are disclosed in the provided filing summary. This is a multi-item filing related to financial results.

12-01-2026

Omada Health, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001781, Size: 176 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, revenue, earnings, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Century Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002748, Size: 7 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This appears to be a multi-item voluntary disclosure, likely including a press release or update furnished under Reg FD with attached exhibits. No specific details on events, transactions, financial metrics, or named entities beyond the filer are disclosed in the provided filing summary.

12-01-2026

Masimo Corp filed an 8-K on January 12, 2026 (AccNo: 0000937556-26-000005, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results disclosure. No specific financial metrics, transaction values, or other quantitative data are mentioned.

12-01-2026

CONMED Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001174947-26-000024, size 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financials, or other content are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure.

12-01-2026

Green Plains Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001309402-26-000009, Size: 289 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position, appointment/resignation status, reasons, or any quantitative data are provided in the available information. Sector is not specified.

12-01-2026

HealthEquity, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001428336-26-000003, size: 174 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other specifics are disclosed in the provided filing summary. All material quantitative data and event descriptions are NOT_DISCLOSED.

12-01-2026

Concentra Group Holdings Parent, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0002014596-26-000009, Size: 2 MB), under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific revenue, earnings, transaction values, or other quantitative financial metrics are mentioned.

12-01-2026

Luminar Technologies, Inc./DE filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000912, Size: 994 KB), disclosing entry into a material definitive agreement under Item 1.01 and notice of delisting or failure to satisfy a continued listing rule under Item 3.01, with financial statements and exhibits under Item 9.01. This is a multi-item mandatory filing signaling potential significant corporate changes. No specific transaction details, values, or financial metrics are disclosed.

12-01-2026

Jazz Pharmaceuticals plc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009899, size 5 MB), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. This is a financial results announcement. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.

12-01-2026

Opus Genetics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000913, Size: 6 MB) under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure or attached exhibits are provided in the filing summary. This appears to be a multi-item informational filing with no transaction values, financial metrics, or other quantitative data disclosed.

12-01-2026

Dianthus Therapeutics, Inc. (/DE/) filed a Form 8-K on 2026-01-12 (AccNo: 0001193125-26-009898, Size: 39 MB) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). Event type is Financial Results from US SEC source. No specific financial metrics, transaction values, or other quantitative details provided in the filing summary.

12-01-2026

GitLab Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001653482-26-000009, Size: 121 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Regulation FD Disclosure under Item 7.01. No specific details on the affected officer, position, reason for change, or any quantitative data are provided in the available information. Sector is not specified.

12-01-2026

Caris Life Sciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0002019410-26-000005, Size: 175 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Norwood Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009896, Size: 151 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure event. No specific financial metrics, transaction values, or other numerical data are mentioned in the provided filing summary.

12-01-2026

AEON Biopharma, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001837607-26-000002, Size: 6 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a general filing from the US SEC with sector not specified. No specific details on the disclosure content, financial statements, exhibits, transaction values, or other numerical data are provided in the filing summary.

12-01-2026

Spyre Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009894, size 16 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other specifics are provided in the filing summary. Sector is not specified.

12-01-2026

Zimmer Biomet Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009895, size: 187 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). Event type is Officer Change from US SEC source. Sector not specified.

12-01-2026

dMY Squared Technology Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001829126-26-000216, Size: 18 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the Regulation FD disclosure content or the nature of financial statements/exhibits are provided in the filing summary. Sector is not specified.

12-01-2026

Planet Labs PBC filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009922, Size: 206 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or specific exhibits are provided in the filing summary. Sector not specified.

12-01-2026

iRhythm Technologies, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002755), reporting multiple material events under Items 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 3.01 (Notice of Delisting or Failure to Satisfy Listing Rule), 3.03 (Material Modifications to Rights of Security Holders), 5.01 (Changes in Control), 5.02 (Departures/Elections/Appointments of Directors/Officers), 5.03 (Amendments to Articles/Bylaws), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements). This is a multi-item filing indicating significant corporate changes, but no specific transaction details, dollar values, or financial metrics are disclosed. Timing compliance and core event details are NOT_DISCLOSED.

12-01-2026

N2OFF, Inc. filed a general filing (likely Form 8-K) on January 12, 2026 (AccNo: 0001493152-26-001247, Size: 200 KB) reporting Item 3.02: Unregistered Sales of Equity Securities. No specific details such as transaction value, share count, parties involved, or financial impacts are disclosed. Sector is not specified.

12-01-2026

Genesco Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009919), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the specific disclosure content, financial statements, or exhibits are provided. This is a general filing from the US SEC with file size 217 KB; sector not specified.

12-01-2026

Sun Country Airlines Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009914, Size: 1 MB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). Sector not specified. No specific details on the agreement, disclosures, transaction value, or financial impacts are provided in the filing summary.

12-01-2026

Alignment Healthcare, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001783, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or specific exhibits are provided. Sector not specified.

12-01-2026

Theriva Biologics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002750, Size: 12 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other events, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

SI-BONE, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001459839-26-000010, Size: 4 MB) reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Orchestra BioMed Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002752, size: 211 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific other event, transaction, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Alphatec Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009910, Size: 269 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific revenue, earnings, transaction values, or other numerical financial metrics are disclosed in the provided filing summary. This is a standard financial results disclosure from the US SEC.

12-01-2026

BioAge Labs, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009911, Size: 339 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure as Items 7.01 and 8.01 are typically voluntary. No specific core events, transactions, financial metrics, or quantitative data are disclosed in the provided filing summary.

12-01-2026

IRIDEX CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009912, Size: 208 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This constitutes a financial results disclosure event. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Innventure, Inc. filed an 8-K on January 12, 2026 (AccNo: 0002001557-26-000002, Size: 152 KB) reporting under Item 8.01 Other Events. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Scholar Rock Holding Corp filed an 8-K on 2026-01-12 (AccNo: 0001104659-26-002757) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results with no specific numerical data, transaction details, or operational metrics provided in the filing summary. Sector not specified.

12-01-2026

Securetech Innovations, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001017386-26-000002, 190 KB), reporting Item 3.02 Unregistered Sales of Equity Securities and Item 9.01 Financial Statements and Exhibits. No specific details on the sales, transaction value, shares, parties, or financial impacts are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Metagenomi, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009928), reporting under Item 5.03 amendments to articles of incorporation or bylaws or a change in fiscal year, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the nature of amendments, disclosures, or exhibits provided in the summary. No quantitative data, transaction values, or other numerical values are disclosed.

12-01-2026

FIVE BELOW, INC filed a Form 8-K on January 12, 2026 (AccNo: 0001177609-26-000003, Size: 421 KB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing summary. All specifics including dollar values, percentages, and impacts are NOT_DISCLOSED.

12-01-2026

Lipocine Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001254, Size: 258 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No details on the specific events, transactions, financial statements, or exhibits are disclosed in the provided summary. Sector not specified.

12-01-2026

MainStreet Bancshares, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001056, Size: 188 KB) under Item 7.01 Regulation FD Disclosure. No core event, transaction details, financial metrics, or other specifics are disclosed in the provided filing information. This is a voluntary disclosure of potentially material nonpublic information.

12-01-2026

KORU Medical Systems, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001161697-26-000027, size 212 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative results are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Bristol Myers Squibb Co filed a Form 8-K on January 12, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). The filing has Accession Number 0001140361-26-000929 and a size of 3 MB. No specific details on the content of the disclosures, events, financials, or exhibits are provided.

12-01-2026

Vor Biopharma Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009961, size 7 MB), disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results with no specific revenue, earnings, transaction values, or other metrics detailed in the provided information. Sector is not specified.

12-01-2026

First Watch Restaurant Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001789940-26-000003, Size: 294 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure from the US market. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

GRAIL, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001786, Size: 2 MB) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results announcement. No specific revenue, earnings, transaction values, or other financial metrics are mentioned in the provided filing summary.

12-01-2026

Lexeo Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010091, Size: 22 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure in the healthcare/biotech sector (sector not specified). No specific event details, financial data, or transaction information are disclosed in the provided filing summary.

12-01-2026

Urban Outfitters Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010089, Size: 199 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financial statements, or exhibits are provided in the filing summary. All quantitative data, named entities beyond the filer, and event specifics are NOT_DISCLOSED.

12-01-2026

Biohaven Ltd. filed an 8-K on January 12, 2026 (AccNo: 0001935979-26-000005, Size: 14 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). Sector not specified. No core event details, transaction values, financial metrics, or other quantitative data disclosed in the provided filing summary.

12-01-2026

Spire Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010094, Size: 805 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other event or attached exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Profound Medical Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000210, size 222 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This appears to be a voluntary disclosure of material nonpublic information with attached exhibits, but no core event details, financial metrics, or transaction specifics are provided in the filing summary. Sector is not specified.

12-01-2026

Bruker Corp filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010106, Size: 206 KB) reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This is a financial results disclosure with no specific numerical financial metrics, transaction details, or guidance provided in the available information. Sector not specified.

12-01-2026

Biodesix Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010114), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This is a multi-item filing for financial results disclosure from the US SEC. No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary.

12-01-2026

Sarepta Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010116, Size: 234 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary. Sector is not specified.

12-01-2026

Forum Energy Technologies, Inc. disclosed an officer change via Form 8-K filed on January 12, 2026 (AccNo: 0001401257-26-000002, Size: 183 KB) under Item 5.02, covering Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the affected position, individual names, appointment or resignation status, reasons, or any quantitative data are provided in the available information. Sector is not specified.

12-01-2026

PTC Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002799, Size: 4 MB) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary financial results filing with no specific revenue, earnings, or transaction details provided. Sector is not specified.

12-01-2026

Wetouch Technology Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003235, size 2 MB), reporting under Item 5.03 amendments to Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses financial statements and exhibits. No specific details on the nature of amendments, transaction values, or financial metrics are provided in the summary.

12-01-2026

Capstone Companies, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001903596-26-000004, Size: 3 MB), reporting under Item 1.01 entry into a material definitive agreement. Sector not specified. No details on the agreement, transaction value, parties, or financial impacts are disclosed in the provided filing summary.

12-01-2026

EQV Ventures Acquisition Corp. filed an 8-K on January 12, 2026 (AccNo: 0001213900-26-003243, Size: 32 MB) announcing a Merger/Acquisition under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits). No specific details on deal structure, parties, valuation, or financial metrics are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Cuentas Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003257, Size: 253 KB) reporting Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing concerning a material event. Sector not specified; no details on the agreement, transaction value, or exhibits provided.

12-01-2026

ZION OIL & GAS INC filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001070, Size: 144 KB) disclosing an officer change under Item 5.02. Item 5.02 covers Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on positions affected, individuals involved, reasons, or compensation are provided.

12-01-2026

ENB Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001174947-26-000030), reporting under Item 8.01 Other Events. No specific details on the event, transaction, financial impacts, or other quantitative data are disclosed in the provided filing information. Sector is not specified.

12-01-2026

Sentient Brands Holdings Inc. filed an 8-K on January 12, 2026 (AccNo: 0001731122-26-000048), reporting under Item 1.02 termination of a material definitive agreement, Item 4.01 changes in certifying accountant, Item 5.02 departures/elections of directors/officers and compensatory arrangements, Item 8.01 other events, and Item 9.01 financial statements/exhibits. No specific transaction values, financial metrics, or named individuals/entities beyond the filer are disclosed. This is a multi-item filing signaling multiple operational and governance changes.

12-01-2026

Savers Value Village, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001883313-26-000006, Size: 251 KB) under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure with no specific revenue, earnings, transaction values, or other metrics detailed in the provided information. Sector is not specified.

12-01-2026

Open Text Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001002638-26-000003, Size: 154 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific other events or financial statements/exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Flanigan's Enterprises Inc. disclosed an officer change via SEC Form 8-K filed on January 12, 2026 (AccNo: 0001174947-26-000032, Size: 187 KB) under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for change, or quantitative data such as compensation amounts are provided in the available information. Sector is not specified.

12-01-2026

FIRST MERCHANTS CORP filed a Form 8-K on January 12, 2026 (AccNo: 0000712534-26-000003, Size: 194 KB), reporting Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the events, transactions, financial impacts, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Satellogic Inc. filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession Number: 0001874315-26-000003, file size 205 KB. Sector not specified; no details on the event provided.

12-01-2026

10x Genomics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001808, Size: 899 KB) under Item 2.02 disclosing Results of Operations and Financial Condition. No specific financial metrics, transaction values, guidance, or other quantitative details are mentioned in the provided filing summary. Sector is not specified.

12-01-2026

Avadel Pharmaceuticals PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002870, Size: 266 KB), reporting under Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing with no specific details on shareholder vote outcomes, events, or exhibits provided in the summary. Sector is not specified.

12-01-2026

Unusual Machines, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001683168-26-000219, Size: 8 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on voluntary disclosure of material information previously shared selectively and attached exhibits. No specific event details, financial metrics, transaction values, or other quantitative data are disclosed in the filing summary.

12-01-2026

NETSTREIT Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001814), disclosing under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or quantitative data are mentioned in the filing summary. This appears to be a standard earnings-related disclosure.

12-01-2026

RMR Group Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002868, Size: 192 KB), disclosing an officer change under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the affected position, appointment/resignation, reasons, or individuals are disclosed in the provided information. Sector is not specified.

12-01-2026

Ares Capital Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002869, Size: 699 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, dollar values, or quantitative impacts disclosed in the provided summary. Sector is not specified.

12-01-2026

BridgeBio Pharma, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000971, Size: 8 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results, but no specific financial metrics, transaction details, or quantitative data are disclosed in the provided information. Items suggest disclosure of earnings or operational updates, likely voluntary under Reg FD.

12-01-2026

Plymouth Industrial REIT, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession Number: 0001193125-26-010364, file size 416 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.

12-01-2026

JOINT Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001612630-26-000008), reporting under Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No details on the agreement, transaction value, or exhibits are disclosed in the provided summary. Sector not specified.

12-01-2026

Alexandria Real Estate Equities, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002862), disclosing an Item 5.02 event related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the officer involved, position affected, nature of change (appointment or resignation), reasons, or any quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

Ribbon Acquisition Corp. filed an 8-K on January 12, 2026 (AccNo: 0001213900-26-003388, Size: 265 KB), disclosing under Item 5.07 the submission of matters to a vote of security holders, likely related to a merger or acquisition. Item 9.01 includes financial statements and exhibits. No specific details on deal structure, parties, valuation, or vote results are provided in the filing summary.

12-01-2026

Aktis Oncology, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010354, Size: 356 KB), reporting under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses financial statements and exhibits. No specific details on the amendments, transaction values, or quantitative financial impacts are provided.

12-01-2026

Direct Digital Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001880613-26-000006, Size: 255 KB), reporting Items 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing classified as a Material Event from US SEC source. No core event details, transaction values, financial impacts, or other specifics are disclosed.

12-01-2026

Natera, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002861, Size: 217 KB) reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This discloses financial results as a US market event. No specific financial metrics, transaction values, or quantitative data are mentioned.

12-01-2026

TRUSTCO BANK CORP NY filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000965, Size: 576 KB), reporting Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

lululemon athletica inc. filed an 8-K on January 12, 2026 (AccNo: 0001397187-26-000005, Size: 293 KB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other quantitative data are explicitly stated in the provided filing summary. All other specifics such as dollar values, percentages, or named entities beyond the filer are NOT_DISCLOSED.

12-01-2026

Diamondback Energy, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001539838-26-000003, Size: 202 KB) under Item 2.02 reporting Results of Operations and Financial Condition. No specific financial metrics, transaction values, revenue, earnings, or other quantitative details are disclosed in the provided filing information. Sector is not specified.

12-01-2026

Ambow Education Holding Ltd. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003384, Size: 266 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the officer, position, appointment/resignation, reasons, or compensation are disclosed.

12-01-2026

Sky Harbour Group Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001099, size 559 KB), reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. This is a multi-item mandatory filing for material events. No specific transaction details, dollar values, named counterparties, or financial metrics are disclosed in the provided summary.

12-01-2026

Actuate Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001683168-26-000217, Size: 236 KB), disclosing under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the Regulation FD disclosure or the nature of the financial statements/exhibits are provided. Sector is not specified.

12-01-2026

Atara Biotherapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010342, Size: 155 KB) reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results and other events. No specific financial metrics, transaction details, or numerical data are disclosed in the provided filing summary.

12-01-2026

INTERGROUP CORP filed a Form 8-K on 2026-01-12 (AccNo: 0001493152-26-001843, Size: 208 KB) disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Event date is January 12, 2026. Sector not specified; no further details on positions, individuals, or reasons provided.

12-01-2026

Heritage Global Inc. announced via 8-K filing on January 12, 2026 (AccNo: 0001193125-26-010341, Size: 1 MB) entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01). Additional disclosures include Regulation FD information (Item 7.01) and financial statements/exhibits (Item 9.01). No details on parties, structure, valuation, or financial impacts are provided.

12-01-2026

Medallion Financial Corp filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010406), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included. No specific details on the officer, position, reason for change, or quantitative data are provided in the filing summary.

12-01-2026

Larimar Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010409, size: 25 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Citigroup Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010408, Size: 298 KB), reporting solely under Item 9.01 for Financial Statements and Exhibits. No details on the specific financial statements, exhibits, transactions, or numerical values are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

NetApp, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010401, Size: 177 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). Specific details including key position affected, appointment or resignation status, reasons, named individuals, and any quantitative data are NOT_DISCLOSED. Sector is not specified.

12-01-2026

First Bancorp, Inc /ME/ filed a Form 8-K on January 12, 2026 (AccNo: 0000765207-26-000003, size: 126 KB), disclosing an Item 5.02 event related to the departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details such as affected positions, individuals involved, reasons for change, or any quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

Shuttle Pharmaceuticals Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001861, Size: 249 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and exhibits under Item 9.01. No specific details on the affected officer, position, reason for change, or compensatory arrangements are provided in the available filing summary. Sector is not specified.

12-01-2026

Pixelworks, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001040161-26-000007, Size: 449 KB) announcing under Item 2.01 the completion of an acquisition or disposition of assets. Item 9.01 includes financial statements and exhibits. No details on parties, structure, valuation, or strategic rationale are disclosed.

12-01-2026

Dynatronics Corp filed an 8-K on 2026-01-12 (AccNo: 0001062993-26-000178, size 221 KB) disclosing bankruptcy or receivership under Item 1.03, triggering events accelerating direct financial obligations under Item 2.04, and departures of directors or certain officers under Item 5.02. No specific financial amounts, transaction values, or other quantitative details are provided. Sector is not specified.

12-01-2026

ANI Pharmaceuticals Inc filed an 8-K on January 12, 2026 (AccNo: 0001023024-26-000005, Size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure from the US market. No specific financial metrics, transaction values, or quantitative data are mentioned.

12-01-2026

Forian Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000976, Size: 500 KB), reporting Items 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 5.07 (Submission of Matters to a Vote of Security Holders), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing classified as a Material Event from US SEC source, with sector not specified. No specific details, transaction values, financial metrics, or named entities beyond the company are disclosed.

12-01-2026

Sonos Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001314727-26-000004, Size: 180 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). The filing also includes Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer, position, reason, or quantitative data provided.

12-01-2026

Bank of Marin Bancorp filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession number is 0001403475-26-000004 with file size 149 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.

12-01-2026

Verizon Communications Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010395, Size: 430 KB), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the affected officer, position (e.g., CEO, CFO), nature of change (appointment or resignation), reasons, or individuals are disclosed. Sector is not specified, and no quantitative financial data is mentioned.

12-01-2026

DESTINATION XL GROUP, INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010389, Size: 240 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item financial results disclosure from the US market with sector not specified. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.

12-01-2026

Wealthfront Corp filed an 8-K on January 12, 2026 (AccNo: 0001628280-26-001819), reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative data are mentioned in the provided filing summary.

12-01-2026

POOL CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010379, Size: 380 KB), disclosing under Item 5.02 a matter involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits are included. No specific details on the officer, position, reason for change, or any quantitative data are provided in the filing summary.

12-01-2026

Compass Digital Acquisition Corp. filed an 8-K on January 12, 2026 (AccNo: 0001493152-26-001853, Size: 1 MB), disclosing under Item 1.01 entry into a Material Definitive Agreement for a Merger/Acquisition event. Item 9.01 includes Financial Statements and Exhibits. No specific details on parties, deal structure, valuation, or sector provided.

12-01-2026

Broadstone Net Lease, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001424182-26-000002, Size: 177 KB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a general filing from the US SEC with sector not specified. No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Copper Property CTL Pass Through Trust filed a Form 8-K on January 12, 2026 (AccNo: 0001837671-26-000004, Size: 2 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financials provided. Sector not specified.

12-01-2026

MASCO CORP /DE/ filed an 8-K on January 12, 2026 (AccNo: 0001213900-26-003396, Size: 188 KB), disclosing under Item 5.02 information regarding departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the officer involved, reason for change, or any quantitative data are provided in the available summary. Sector is not specified.

12-01-2026

Rafael Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003411, size: 203 KB), reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No details on the specific matters submitted, vote results, or any financial implications are disclosed in the provided filing summary. This is a standard disclosure related to shareholder votes.

12-01-2026

CAVA GROUP, INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001818, Size: 160 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, appointment/resignation status, reasons, or compensation are provided in the summary. Sector is not specified.

12-01-2026

BIOCRYST PHARMACEUTICALS INC filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000213, Size: 246 KB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed.

12-01-2026

FIRST NORTHERN COMMUNITY BANCORP filed a Form 8-K on January 12, 2026 (AccNo: 0001114927-26-000002, Size: 357 KB), disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on positions, individuals, reasons, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Health Catalyst, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001636422-26-000006, Size: 434 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, but no specific revenue, earnings, transaction values, or other quantitative metrics are mentioned. Sector is not specified.

12-01-2026

Sanmina Corp filed an 8-K on January 12, 2026 (AccNo: 0000897723-26-000004, Size: 1 MB) announcing under Item 2.01 the completion of an acquisition or disposition of assets. Item 9.01 includes financial statements and exhibits. No details on parties involved, deal structure, valuation, or strategic rationale are disclosed.

12-01-2026

Calumet, Inc. (/DE) filed Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010438, Size: 927 KB), disclosing entry into a Material Definitive Agreement (Item 1.01), creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement (Item 2.03), Regulation FD Disclosure (Item 7.01), and Financial Statements and Exhibits (Item 9.01). This multi-item filing signals significant corporate developments involving new agreements and financial commitments. No transaction values, parties, financial metrics, or further details are provided in the summary.

12-01-2026

Exelixis, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000939767-26-000003, Size: 430 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, transaction values, or other quantitative data are disclosed in the provided filing summary. This is a multi-item filing announcing financial results.

12-01-2026

Invesco Ltd. filed a Form 8-K on January 12, 2026 (AccNo: 0000914208-26-000010, Size: 228 KB) under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). No core event, transaction details, financial metrics, or quantitative data are explicitly stated in the filing summary. All specific impacts, values, and entities beyond the filer are NOT_DISCLOSED.

12-01-2026

Workhorse Group Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001835, Size: 136 KB) disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on individuals involved, positions, reasons for change, or any numerical data are provided. Sector is not specified.

12-01-2026

Matthews International Corp filed an 8-K on January 12, 2026 (AccNo: 0000063296-26-000006, Size: 176 KB) reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Quest Diagnostics Inc filed an 8-K on January 12, 2026 (AccNo: 0000947871-26-000025, Size: 7 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Crown Castle Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001051470-26-000003, Size: 573 KB) reporting financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results disclosure. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.

12-01-2026

T-Mobile US, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010485, Size: 958 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

RxSight, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010478, Size: 196 KB) disclosing an officer change under Item 5.02, alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer position, appointment/resignation, reasons, or individuals involved are provided. No quantitative data, named people, or additional facts are disclosed in the summary.

12-01-2026

Syndax Pharmaceuticals Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010486, Size: 225 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This constitutes a multi-item filing for financial results in the US equity markets. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Zymeworks Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010480, Size: 300 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). Specific details on the officer involved, position affected, reason for change, or any quantitative financial metrics are NOT_DISCLOSED. Sector is not specified.

12-01-2026

Crescent Energy Co filed an 8-K on January 12, 2026 (AccNo: 0001866175-26-000006, Size: 151 KB) under Item 2.02 reporting Results of Operations and Financial Condition. No specific financial metrics, transaction details, revenue, earnings, or other quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Chipotle Mexican Grill Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001058090-26-000002, Size: 174 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific details on the officer involved, position, appointment/resignation, reasons, or compensation are provided in the summary. Sector not specified.

12-01-2026

Artisan Partners Asset Management Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001517302-26-000003, Size: 242 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on the officer involved, position affected, reason for change, or any quantitative data such as compensation or share counts are provided in the summary. Sector is not specified.

12-01-2026

Babcock & Wilcox Enterprises, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002884, Size: 247 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). No specific details on the affected position, individual names, appointment/resignation status, reasons, or compensation are disclosed in the provided information. Sector is not specified.

12-01-2026

Pelthos Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001753926-26-000094, Size: 6 MB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Regulation FD Disclosure under Item 7.01. No specific details on the affected officer, position, appointment/resignation, reasons, or compensation provided in the filing summary. Sector not specified.

12-01-2026

GeoVax Labs, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001113, Size: 849 KB), reporting Items 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), and 9.01 (Financial Statements and Exhibits). No specific details on the modifications, amendments, or exhibits are disclosed in the provided information. All transaction values, financial metrics, and quantitative impacts are NOT_DISCLOSED.

12-01-2026

Option Care Health, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002887, Size: 6 MB) reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary. This appears to be a multi-item voluntary financial results disclosure.

12-01-2026

Regions Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001281761-26-000003, Size: 271 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer involved, position affected, appointment/resignation status, reasons, or quantitative data are provided.

12-01-2026

Jamf Holding Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002883, Size: 185 KB) disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the officer, position, appointment/departure, reasons, or compensation provided in the available summary. Sector not specified.

12-01-2026

Allurion Technologies, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010462, Size: 257 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, revenue, earnings, transaction values, or quantitative performance data are disclosed in the provided filing summary. This constitutes a standard financial results disclosure without detailed operational or strategic insights.

12-01-2026

BioAtla, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010458), reporting multiple items: unregistered sales of equity securities (Item 3.02), amendments to articles of incorporation or bylaws/change in fiscal year (Item 5.03), submission of matters to a vote of security holders (Item 5.07), other events (Item 8.01), and financial statements/exhibits (Item 9.01). This is a multi-item filing with no specific transaction details, dollar values, share counts, or other numerical data disclosed in the provided information. All quantitative metrics are NOT_DISCLOSED.

12-01-2026

Mobile Global Esports, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003416, Size: 199 KB), disclosing under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 reports financial statements and exhibits. No further details on the amendments, fiscal year change, or exhibits are provided.

12-01-2026

TrueBlue, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000768899-26-000002, Size: 180 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, appointment/resignation, reasons, or compensation provided. Sector not specified.

12-01-2026

Sky Quarry Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001096906-26-000077, Size: 486 KB), reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, parties involved, or financial impacts are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Truist Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0000092230-26-000006, Size: 395 KB) under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the core event, transaction value, financial impacts, or other specifics are provided in the filing summary. This appears to be a multi-item voluntary disclosure related to material nonpublic information.

12-01-2026

MaxCyte, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002901, Size: 187 KB), reporting under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a financial results disclosure with no specific revenue, earnings, or other metrics detailed in the provided filing summary. All quantitative financial data is NOT_DISCLOSED.

12-01-2026

SAB Biotherapeutics, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010515, size: 14 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with sector not specified. No details on the core event, financials, or exhibits content are provided.

12-01-2026

Olema Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010507, Size: 21 MB) disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results in the US equity market. No specific revenue, earnings, transaction values, or other financial metrics are mentioned in the provided filing summary.

12-01-2026

Assertio Holdings, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession Number: 0001104659-26-002899, file size 190 KB. No details on the core event, transaction values, financial impacts, or other specifics disclosed in the provided filing summary.

12-01-2026

DELCATH SYSTEMS, INC. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010498, Size: 15 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

BioMarin Pharmaceutical Inc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010508, Size: 2 MB) announcing financial results under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary. This is a standard financial results disclosure from the US SEC.

12-01-2026

USBC, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001654954-26-000275, Size: 142 KB), disclosing an event under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on affected positions (e.g., CEO, CFO), appointment/resignation status, reasons, individuals involved, or quantitative data are provided in the summary. Sector is not specified.

12-01-2026

Oncolytics Biotech Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002863, Size: 246 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Astrana Health, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002866, Size: 6 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event, transaction details, financial metrics, or quantitative data are specified in the provided filing summary. Sector is not specified.

12-01-2026

SunPower Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003483, Size: 291 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), and Item 9.01 (Financial Statements and Exhibits). No specific details on the agreement, transaction value, share count, or other quantitative data are disclosed in the provided filing summary.

12-01-2026

Bio Green Med Solution, Inc. filed a Form 8-K on January 12, 2026, under Item 8.01 Other Events. Accession number: 0001493152-26-001848; file size: 270 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.

12-01-2026

P10, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010556, Size: 318 KB), reporting under Items 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary and mandatory disclosure filing with no specific details on events, transactions, or financial impacts provided. All quantitative data, transaction values, and core event descriptions are NOT_DISCLOSED.

12-01-2026

5E Advanced Materials, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010363, Size: 148 KB), reporting under Item 3.02 regarding unregistered sales of equity securities. No specific details on transaction value, share count, parties involved, or financial impacts are disclosed in the provided information. This is a material event disclosure with limited available data.

12-01-2026

GlobalTech Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001477932-26-000161, Size: 179 KB), disclosing changes in certifying accountant (Item 4.01), departure of directors or certain officers, election/appointment of directors/officers, or compensatory arrangements (Item 5.02), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific names, positions, reasons, quantitative data, or further details provided. Sector not specified.

12-01-2026

Apellis Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010540, Size: 208 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a standard disclosure for financial results without additional context on performance.

12-01-2026

Moody's Corp /DE/ filed an 8-K on January 12, 2026 (AccNo: 0001059556-26-000004, Size: 4 MB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position, appointment/resignation status, reasons, or quantitative data are provided in the filing summary. Event classified as Officer Change from US SEC source.

12-01-2026

AllianceBernstein Holding L.P. filed a Form 8-K on January 12, 2026 (AccNo: 0000825313-26-000009, Size: 193 KB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing summary. This appears to be a voluntary disclosure of material nonpublic information with attached exhibits.

12-01-2026

PMGC Holdings Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003480, Size: 277 KB), reporting Entry into a Material Definitive Agreement under Item 1.01 and Financial Statements and Exhibits under Item 9.01. No details on the agreement's terms, counterparties, transaction value, or financial impacts are explicitly stated in the provided filing summary. Sector is not specified.

12-01-2026

Safe & Green Development Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003507, Size: 726 KB), reporting entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), with financial statements and exhibits (Item 9.01). Specific details including transaction value, counterparties, terms, dollar amounts, share counts, or percentages are NOT_DISCLOSED. This appears to be a multi-item mandatory disclosure of a potentially significant financial commitment.

12-01-2026

EOG Resources Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000821189-26-000012, Size: 169 KB) under Item 2.02 disclosing Results of Operations and Financial Condition. No specific financial metrics, transaction details, dollar values, percentages, or other quantitative data are mentioned in the provided filing summary. Sector is not specified.

12-01-2026

National Healthcare Properties, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001561032-26-000005, Size: 542 KB), reporting multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 3.03 (Material Modifications to Rights of Security Holders), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific transaction values, financial metrics, named entities beyond the filer, or quantitative details are disclosed in the provided filing summary. This is a multi-item mandatory filing signaling potentially significant corporate changes.

12-01-2026

Travere Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001438533-26-000003, Size: 222 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. This is a financial results disclosure with no specific numerical data, transaction details, or strategic insights provided in the filing summary. Sector not specified.

12-01-2026

Inspire Medical Systems, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001609550-26-000006, Size: 5 MB), reporting an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer involved, position affected, reason for change, or any quantitative data such as transaction values, share counts, or financial metrics are disclosed. Sector is not specified.

12-01-2026

Evofem Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001886, Size: 14 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the disclosure or specific exhibits are provided. Sector is not specified.

12-01-2026

Belpointe PREP, LLC filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001887, Size: 326 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No details on the agreement, transaction value, parties, or financial impacts are disclosed in the provided summary. Sector not specified.

12-01-2026

Grace Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000995, Size: 337 KB) disclosing an officer change under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, or quantitative data are provided in the available information.

12-01-2026

Galectin Therapeutics Inc. disclosed an officer change via Form 8-K filed on January 12, 2026 (AccNo: 0001140361-26-000994, Size: 151 KB). The filing pertains to Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on positions, individuals, reasons, or compensation are provided in the available summary.

12-01-2026

AMERICAN EAGLE OUTFITTERS INC filed a General Filing (likely Form 8-K) on January 12, 2026, reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. Accession Number: 0001193125-26-010573; File Size: 229 KB. No details on the content of the disclosure or exhibits are provided.

12-01-2026

ASP Isotopes Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001477932-26-000162, Size: 150 KB), disclosing an officer change under Item 5.02. Item 5.02 covers Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the officer, position, appointment/resignation, reasons, or impacts are disclosed.

12-01-2026

Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010582), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, or other quantitative data are disclosed in the provided filing summary; sector not specified.

12-01-2026

Optimum Communications, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002909, size 1 MB), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, with Item 9.01 financial statements and exhibits. No specific transaction details, dollar values, counterparties, strategic context, or financial impacts are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Waters Corp (/DE/) filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010633, Size: 2 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the disclosure or exhibits are provided in the filing summary. Sector not specified.

12-01-2026

Amphastar Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001297184-26-000002, Size: 219 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. No details on the agreement, disclosures, transaction value, or financial impacts are provided in the filing summary. This is a multi-item mandatory filing for material events.

12-01-2026

RAYONIER ADVANCED MATERIALS INC. filed a Form 8-K on 2026-01-12 (AccNo: 0001597672-26-000003, Size: 197 KB) disclosing Item 5.02 regarding Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific names, transaction values, or additional details are provided in the filing summary. Sector not specified.

12-01-2026

Yum China Holdings, Inc. disclosed an officer change event via SEC Form 8-K filed on January 12, 2026 (AccNo: 0001193125-26-010568, Size: 204 KB). The filing pertains to Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the affected officer, nature of change, reasons, or quantitative data are provided in the available information.

12-01-2026

Shake Shack Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001620533-26-000008), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This discloses financial results. No specific financial metrics, transaction values, or quantitative data are provided in the filing summary.

12-01-2026

Eagle Point Income Co Inc. filed a Form 8-K on January 12, 2026, under Item 8.01 Other Events. Accession number: 0001104659-26-002938; filing size: 316 KB. No details on the specific event, transaction, financial impact, or other quantitative data are disclosed in the provided filing summary.

12-01-2026

GeneDx Holdings Corp. filed a Form 8-K on 2026-01-12 (AccNo: 0001818331-26-000005, Size: 5 MB) under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This discloses financial results but no specific revenue, earnings, transaction values, or other numerical metrics are mentioned in the provided filing summary. Sector is not specified.

12-01-2026

AMC Entertainment Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002937, Size: 240 KB) disclosing entry into a Material Definitive Agreement under Item 1.01. Item 9.01 reports Financial Statements and Exhibits. No details on the agreement's nature, parties, value, or financial impacts are provided in the summary.

12-01-2026

Core Natural Resources, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001710366-26-000002, Size: 139 KB), reporting Item 1.04 on Mine Safety - Reporting of Shutdowns and Patterns of Violations. No specific details on shutdowns, violations, financial impacts, or quantitative data are disclosed in the provided filing summary. This appears to be a mandatory single-item disclosure with potential operational risks in the natural resources sector.

12-01-2026

Beyond Meat, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010677, size 158 KB), reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. No specific details on the agreement, transaction value, terms, or parties are disclosed in the provided filing summary. This is a multi-item mandatory filing signaling potentially significant contractual and financial commitments.

12-01-2026

Eagle Point Credit Co Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002934, Size: 720 KB) reporting under Item 8.01 Other Events. No specific details on the event, transaction, financial impacts, or other quantitative data are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Gyrodyne, LLC filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001119, Size: 2 MB), reporting under Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. This is a multi-item mandatory disclosure of a core material event, but specific details on the agreement, transaction value, parties, or financial impacts are NOT_DISCLOSED in the provided information. No quantitative data, named entities beyond the filer, or further context is available.

12-01-2026

DIRTT Environmental Solutions Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010658, Size: 194 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer position, appointment/resignation, reasons, or quantitative data are provided in the summary.

12-01-2026

AIM ImmunoTech Inc. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other specifics are disclosed in the provided filing summary. All quantitative data and substantive content are NOT_DISCLOSED.

12-01-2026

iBio, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002940), reporting multiple items including Entry into a Material Definitive Agreement (Item 1.01), Unregistered Sales of Equity Securities (Item 3.02), Regulation FD Disclosure (Item 7.01), and Financial Statements and Exhibits (Item 9.01). This is a multi-item filing with no specific details on the agreement, transaction terms, values, or parties provided in the summary. All quantitative and qualitative details such as dollar values, share counts, or strategic context are NOT_DISCLOSED.

12-01-2026

Kiniksa Pharmaceuticals International, plc filed an 8-K on January 12, 2026 (AccNo: 0001730430-26-000005, Size: 217 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction values, or detailed results are disclosed in the provided filing information. Sector is not specified.

12-01-2026

SURO CAPITAL CORP. filed an 8-K on January 12, 2026 (AccNo: 0001493152-26-001901, size: 321 KB) disclosing under Item 2.02 Results of Operations and Financial Condition, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing related to financial results. No specific financial metrics, transaction details, or quantitative impacts are disclosed in the provided filing summary.